GenAI has emerged as a beacon of innovation, offering businesses the promise of transformative capabilities. Yet, as organizations hasten to harness its potential, a glaring problem becomes evident: the journey from pilot to full-scale production is riddled with unexpected pitfalls, particularly in crafting a robust business case. This article delves into some of the reasons why GenAI initiatives fail to scale from promising pilots to production systems.
In 2023, many senior executives across various sectors were excited by the potential of GenAI to revolutionize business operations. With substantial investments and numerous pilots underway, the anticipation was palpable. However, the reality that unfolded was starkly different—most GenAI pilots struggled to progress beyond the experimental phase. Insights from a panel convened by Everest Group, in collaboration with Yates Ltd. and CalypsoAI, featuring 50 CIOs and CTOs from Fortune 500 companies, shed light on this dilemma. Despite their initial enthusiasm, these leaders encountered significant barriers, leading to a phenomenon termed "pilot fatigue."
Let's dive deeper into one of the leading causes of failure to scale beyond the pilot phase – the failure of the business case. We will then outline a systematic method for developing comprehensive business cases.
